Get Live Data

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Scancell Holdings Share Price
  4. Scancell Holdings Share News
  5. UK Earnings, Trading Statements Calendar - Next 7 Days

Pin to quick picksScancell Holdings Share News (SCLP)

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

Scancell Holdings Information

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.50
Ask: 11.00
Change: 0.50 (5.13%)
Spread: 1.50 (15.789%)
Open: 9.75
High: 10.25
Low: 9.75
Prev. Close: 9.75
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Earnings, Trading Statements Calendar - Next 7 Days

Tue, 18th Sep 2018 16:19

Wednesday 19 September 
KingfisherHalf Year Results
Babcock InternationalTrading Statement 
Stagecoach GroupTrading Statement 
RA InternationalHalf Year Results
Yu GroupHalf Year Results
Alliance PharmaHalf Year Results
Cello Health GroupHalf Year Results
Accesso TechnologyHalf Year Results
Greencoat RenewablesHalf Year Results
ErgomedHalf Year Results
QuixantHalf Year Results
EKFHalf Year Results
Thursday 20 September 
IG GroupQ1 Results
Kier GroupHalf Year Results
SOCO InternationalHalf Year Results
Safestyle UKHalf Year Results
City PubHalf Year Results
hVIVOHalf Year Results
LamprellHalf Year Results
Brooks Macdonald GroupFull Year Results
ScisysHalf Year Results
Venture Life GroupHalf Year Results
Inland HomesFull Year Results
Modern WaterHalf Year Results
French ConnectionHalf Year Results
FW ThorpeFull Year Results
Friday 21 September 
Smiths GroupFull Year Results
SIGHalf Year Results
M&C SaatchiHalf Year Results
Triple Point Social HousingHalf Year Results
New Star Investment TrustFull Year Results
Monday 24 September 
Pennon GroupTrading Statement 
Gama AviationHalf Year Results
XLMediaHalf Year Results
KapeHalf Year Results
MaxcyteHalf Year Results
InstemHalf Year Results
Trinity ExplorationHalf Year Results
River & Mercantile GroupFull Year Results
DeltexHalf Year Results
Tuesday 25 Setember 
NextHalf Year Results
AG BarrHalf Year Results
Close BrothersFull Year Results 
OsiriumHalf Year Results
FireAngel SafetyHalf Year Results
Card FactoryHalf Year Results
S&UHalf Year Results
Keystone LawHalf Year Results
Altitude GroupHalf Year Results
Animalcare GroupHalf Year Results
EbiquityHalf Year Results
Menhaden CapitalHalf Year Results
WANdiscoHalf Year Results
Mortgage Advice BureauHalf Year Results
Learning TechnologiesHalf Year Results
Thomas Cook GroupTrading Statement 
United UtilitiesTrading Statement 
Hotel Chocolat GroupFull Year Results 
Harvey Nash GrouipHalf Year Results
Moss BrosHalf Year Results
SSEFinancial Outlook Statement
Blancco Technology GroupFull Year Results 
ScancellFull Year Results 
  

More News
6 Jun 2014 08:54

Scancell Holdings ImmunoBody technology receives US approval

AIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US. The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology. This patent is expect

Read more
6 Jun 2014 08:52

Scancell Granted US Patent For DNA Immunobody Technology

LONDON (Alliance News) - Scancell Holdings PLC said Friday its DNA Immunobody technology platform had been granted a patent by the US Patent and Trademark Office. Scancell said the patent was key for the protection of its pipeline of vaccines utilising the technology. It has already been gr

Read more
2 Jun 2014 11:08

Scancell reports encouraging results of melanoma treatment

Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electropo

Read more
2 Jun 2014 10:39

UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 - WINNERS
-------
Anglo American, up 1.9%, Rio Tinto, up 1.7%, Glencore, up 1.4

Read more
2 Jun 2014 08:04

Scancell Rises As It Gets More Good Results From Skin Cancer Treatment Trial

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Monday after it said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "h

Read more
27 May 2014 12:47

Oxford Technology NAV Declines, Appealing VCT Status Withdrawal

LONDON (Alliance News) - Oxford Technology VCT PLC saw its net asset value per share decline in the year to end-February, and said it was appealing the withdrawal of its venture capital trust status. The trust posted a net asset value per share of 65 pence per share, down from 74 pence in t

Read more
15 May 2014 12:46

Scancell Holdings To Present Phase I/II ImmunoBody Trial Data At ASCO

LONDON (Alliance News) - Scancell Holdings PLC said Thursday that it will announce the latest data from its ongoing Phase I/II clinical trial of its SCIB1 ImmunoBody treatment for stage III/IV melanoma will be presented at the American Society of Clinical Oncology meeting in Chicago at the end of

Read more
1 May 2014 13:03

UK MIDDAY BRIEFING: Lloyds Kicks Off Bank Season With Improvement

LONDON (Alliance News) - Lloyds Banking Group kicked off the first-quarter bank earnings season Thursday, reporting that its pretax profit dropped by a third to GBP1.37 billion after last year was buoyed by gains on the sale of government securities.

However, its un

Read more
1 May 2014 11:27

UK WINNERS & LOSERS: Lloyds Atop FTSE 100 Risers; Weir Leads Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Lloyds Banking Group, up 4.8%. The banking group is the biggest riser in the

Read more
1 May 2014 10:29

Scancell Rises As Long-Time Consultant Joins Its Board

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Thursday after it appointed long-time consultant Dr Sally Adams to its board as development director with immediate effect. In a statement, the company, which is developing immunotherapies to treat

Read more
4 Apr 2014 09:55

Scancell To Announce Phase I/II Of Melanoma Clinical Trial On April 8

LONDON (Alliance News) - Scancell Holdings PLC Friday said that it will announce the results of phase one and two of its clinical trial in patients with stage three and four melanoma at the American Association for Cancer Research annual meeting in San Diego next Tuesday. Scancell Holdings

Read more
21 Mar 2014 09:11

Scancell Holdings Completes Phase 1 Of Melanoma Clinical Trial

LONDON (Alliance News) - Scancell Holdings PLC Friday said it has completed patient dosing with 8mg of SCIB1 ImmunoBody in part one of its on-going phase 1/2 clinical trial in patients with Stage III/IV melanoma. The trial followed a study the firm conducted which showed that a 4mg dose of

Read more
18 Feb 2014 09:19

Scancell Says Patent Application For Cancer Fighting Platform Published

LONDON (Alliance News) - Scancell Holdings PLC Tuesday said its patent application for Moditope has been published, with a view to guarding the platform until 2033 once the patent is granted. In a statement, Scancell said the application for the Modicope platform describes how it uses certa

Read more
11 Feb 2014 09:50

Scancell Gets US Orphan Drug Tag For Metastatic Melanoma Treatment

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday its SCIB1 ImmunoBody metastatic melanoma treatment had been granted orphan drug designation by the US Food and Drug Administration. This designation means that Scancell can qualify for a 50% tax credit for clinical trials of the tr

Read more
11 Feb 2014 09:36

CORRECT: UK MORNING BRIEFING: Shares Open Higher But Barclays Down On Results

Read more

891011121314151617

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.